← Back to Clinical Trials
Recruiting NCT04855773

NCT04855773 Comparing Mobile Health Strategies to Improve Pre-exposure Prophylaxis Use (PrEP) for HIV Prevention

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT04855773
Status Recruiting
Phase
Sponsor Public Health Foundation Enterprises, Inc.
Condition HIV Infections
Study Type INTERVENTIONAL
Enrollment 300 participants
Start Date 2021-07-21
Primary Completion 2023-08

Eligibility & Interventions

Sex All sexes
Min Age 15 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
PrEPmateDot Diary

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 300 participants in total. It began in 2021-07-21 with a primary completion date of 2023-08.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The purpose of this study is to compare the effectiveness of two mobile health technologies (text messaging or a mobile app) designed to help people take HIV pre-exposure prophylaxis (PrEP) as directed by the clinic. PrEP is the use of a daily anti-HIV medications by HIV-negative people to help prevent HIV infection.

Eligibility Criteria

Inclusion Criteria: * Self-identifies as a cisgender man, transgender man (assigned female at birth, trans-masculine spectrum), or transgender woman (assigned male sex at birth, trans-feminine spectrum) * Report sex with a cisgender man or transgender woman or any individual assigned male sex at birth in the past 12 months * Age 15 years or older * Willing and able to provide written informed consent * Owns an iOS or Android mobile phone and able to access the internet and send and receive text messages * Able to understand, read, and speak English or Spanish * Newly initiated PrEP or currently on PrEP and at risk for PrEP discontinuation based on at least one of the following: * Initiated PrEP within the past 6 months, or * Has any of the following risk factors for PrEP discontinuation: missed clinic visits; age \< 30; African-American or Latino; transgender gender identity; or self-reported illicit substance use Exclusion Criteria: * Currently enrolled in another PrEP intervention study * Unable to complete 12 month study participation * Any medical, psychiatric, or social condition or other responsibilities that, in the judgment of the investigator, would make participation in the study unsafe, complicate interpretation of study outcome data, or otherwise interfere with achieving the study objectives.

Frequently Asked Questions

Who can join the NCT04855773 clinical trial?

This trial is open to participants of all sexes, aged 15 Years or older, studying HIV Infections. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT04855773 currently recruiting?

Yes, NCT04855773 is actively recruiting participants. Visit ClinicalTrials.gov or contact Public Health Foundation Enterprises, Inc. to inquire about joining.

Where is the NCT04855773 trial being conducted?

This trial is being conducted at San Francisco, United States, San Francisco, United States, Washington D.C., United States, Miami, United States.

Who is sponsoring the NCT04855773 clinical trial?

NCT04855773 is sponsored by Public Health Foundation Enterprises, Inc.. The trial plans to enroll 300 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology